For the explanations, the persistent involvement of T cells in tumor immunity was balanced by PD-L1 engagement, which is induced by IFN-γ as an adaptive mechanism and thus exactly appropriate for anti-PD1/PD-L1 therapy (46). This evidence concerns the gene CD274 and neoplasm.